jCyte is a clinical-stage company focused on the application of progenitor cell-based technology in retinal diseases. The Company's allogeneic product candidate, jCell, is delivered by simple intravitreal injection without the need for surgery or immune suppression. jCyte has completed a phase 1/2a, phase 1/2a extension and phase 2b clinical trials testing jCell in patients with Retinitis Pigmentosa.
Company Details
Jcyte, Inc. Questions
Jcyte, Inc.'s website is jcyte.com
Jcyte, Inc.'s LinkedIn profile is https://www.linkedin.com/company/jcyte-incorporated
Jcyte, Inc. has
10 employees.
View email and phone details for 10
employees at Jcyte, Inc..
Jcyte, Inc.'s industry is
Biotechnology
Jcyte, Inc.'s top competitors are
4d Molecular Therapeutics,
Endogena Therapeutics, Inc.,
Ocugen,
Eyepoint,
Ocular Therapeutix, Inc.,
Ray Therapeutics, Inc.,
Ophthalmology Innovation Source,
Agios Pharmaceuticals,
Reneuron Group Plc,
Nanoscope Therapeutics Inc..
Jcyte, Inc.'s support email address is info@jcyte.com
Jcyte, Inc.'s categories are Biotechnology
